Sana Biotechnology (NASDAQ:SANA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02, Zacks reports.
Sana Biotechnology Price Performance
Shares of SANA stock remained flat at $1.81 during mid-day trading on Friday. 4,857,620 shares of the stock were exchanged, compared to its average volume of 3,309,512. The company has a market capitalization of $408.11 million, a P/E ratio of -1.29 and a beta of 1.75. The company has a fifty day moving average price of $1.93 and a 200 day moving average price of $2.48. Sana Biotechnology has a twelve month low of $1.26 and a twelve month high of $9.49.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on SANA shares. Citizens Jmp raised shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a research report on Tuesday, March 18th. HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Sana Biotechnology in a report on Thursday, April 24th. Finally, Jefferies Financial Group initiated coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They issued a "buy" rating and a $7.00 target price on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Sana Biotechnology currently has an average rating of "Moderate Buy" and a consensus price target of $10.80.
Check Out Our Latest Report on SANA
About Sana Biotechnology
(
Get Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
